Home > Boards > US Listed > Medical - Drugs > MyMD Pharmaceuticals Inc (MYMD)

Important statement from April 16, 2021 press release:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
leifsmith Member Profile
 
Followed By 58
Posts 11,914
Boards Moderated 0
Alias Born 02/09/09
160x600 placeholder
MyMD Pharmaceuticals Set to Join Russell Microcap® Index Business Wire - 6/7/2021 10:02:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/18/2021 6:11:59 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/18/2021 6:07:21 AM
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board Business Wire - 5/17/2021 9:00:00 AM
MyMD Pharmaceuticals Schedules Business Update Conference Call Business Wire - 5/12/2021 9:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/12/2021 6:05:34 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/11/2021 4:28:20 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 4/28/2021 5:26:41 PM
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Dr... Business Wire - 4/28/2021 10:13:00 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/27/2021 6:02:14 AM
MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent & Trademark Office for Synthetic Cannabinoid C... Business Wire - 4/22/2021 9:20:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/22/2021 6:04:24 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 5:55:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 4:55:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 4:54:18 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/21/2021 4:49:54 PM
MyMD Pharmaceuticals Begins Trading on Nasdaq Business Wire - 4/19/2021 9:00:00 AM
leifsmith   Thursday, 04/22/21 10:20:26 AM
Re: None
Post # of 82 
Important statement from April 16, 2021 press release:
Quote:
MYMD-1 has been shown to be effective in regulating the immune system from causing age-related diseases in preclinical studies. MyMD believes that it is the first oral small molecule regulator of tumor necrosis factor alpha (TNF-a) capable of crossing the blood-brain barrier. Additionally, a recent study from the Eurofins Discovery human phenotypic screening platform revealed the potential of MYMD-1 to be developed as a therapy for fibrosis.

After researching the relationships between inflammation, disease, and TNF-a, and personally witnessing the results from use of anatabine-citrate (an earlier closely related molecule), I conclude that the choice of MyMD for a company name may not be much of an exaggeration.

April 16, 2021 press release

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences